NR565 Week 6 Study Outline 2021/2022

NR565 Week 6 Study Outline 2021/2022 Many questions are written to assess your clinical application of the material from the textbook, in real-world scenarios. Chapter 24: Drugs used in treating infectious diseases (p. 760-796) Antimycobacterials-isoniazid (INH), rifamycin (RIF), pyrazinamide (PZA), ethambutol (EMB) Spectrum of coverage for various organisms- treats TB Pharmacodynamics- INH-interferes with lipid and nucleic acid biosynthesis. RIFInhibits RNA synthesis. Diffuses into all body fluids, decreased by stomach acid (take on empty stomach). Pharmacokinetics-Well absorbed orally and penetrate cells effectively. Genetics play a role in how fast INH is metabolized in liver. Pharmacotherapeutics- Use cautiously with liver, renal, HIV, pregnant, and neuropathy. Clinical indications & dosing-Initial phase-INH, RIF, PZA, EMB for 2 months, continuation phase-INH and RIF for 4-7 months. ADRs-peripheral neuropathy, restlessness, twitching, insomnia, hepatic toxicity, N/V/D Monitoring -Directly observed therapy (DOT), monitor drug interactions RIF is an inducer of CYP 450 enzyme. Antivirals (Nucleoside analogues) Spectrum of coverage for va